Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antiaggregation: aspirin].

A Eichenberger1, L Pontiggia, J H Beer

  • 1Departement Innere Medizin, Kantonsspital Baden. adrian.eichenberger@ksb.ch

Therapeutische Umschau. Revue Therapeutique
|March 18, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mental health management in the context of TB care in the WHO European Region: a consensus statement.

IJTLD open·2026
Same author

[The possible benefit of artificial intelligence in an organized population-related screening program : Initial results and perspective].

Radiologie (Heidelberg, Germany)·2024
Same author

In vitro fertilization exacerbates stroke size and neurological disability in wildtype mice.

International journal of cardiology·2021
Same author

Comparative effectiveness of antiretroviral drug classes for the treatment of HIV infection in patients with high viral loads: a multicentre retrospective cohort study.

HIV medicine·2020
Same author

Tumour Necrosis Factor-α Inhibition Improves Stroke Outcome in a Mouse Model of Rheumatoid Arthritis.

Scientific reports·2019
Same author

Frequency of use and acceptability of clinical prediction rules for pulmonary embolism among Swiss general internal medicine residents.

Thrombosis research·2017

Aspirin effectively prevents secondary cardiovascular events, with a number needed to treat of 25. However, it carries risks of bleeding, necessitating careful consideration for primary prevention in high-risk individuals.

Area of Science:

  • Cardiology
  • Pharmacology
  • Preventive Medicine

Background:

  • Randomized trials confirm aspirin's efficacy as an antiplatelet agent.
  • Aspirin is established for secondary prevention of cardiovascular events.

Purpose of the Study:

  • To evaluate the benefits and risks of aspirin therapy.
  • To define guidelines for aspirin use in primary and secondary prevention.

Main Methods:

  • Review of randomized controlled trials on aspirin.
  • Analysis of number needed to treat (NNT) and number needed to harm (NNH) data.
  • Assessment of risk stratification models for primary prevention.

Main Results:

  • NNT for vascular event prevention is approximately 25.

Related Experiment Videos

  • NNH for cerebral bleeding is about 1,000; for severe extracerebral bleeding, 100-200.
  • Primary prevention is recommended for high-risk patients (≥1-1.5% annual risk).

    • Conclusions:

    • Aspirin is a valuable tool for secondary cardiovascular event prevention.
    • Risk-benefit assessment is crucial, especially for primary prevention.
    • Further discussion on mechanisms, interactions, and aspirin resistance is warranted.